Rapid drug desensitization to taxanes: a descriptive study from Turkey.

IF 1 4区医学 Q4 ONCOLOGY

Journal of Oncology Pharmacy Practice Pub Date : 2024-12-01 Epub Date: 2023-11-07 DOI:10.1177/10781552231213318

Selma Yeşilkaya, Kurtuluş Aksu, Gürgün Tuğçe Vural Solak, Şenay Demir, Musa Topel, Dilek Çuhadar Erçelebi, İlkay Koca Kalkan, Hale Ateş, Gözde Köycü Buhari, Sakine Nazik Bahçecioğlu

{"title":"Rapid drug desensitization to taxanes: a descriptive study from Turkey.","authors":"Selma Yeşilkaya, Kurtuluş Aksu, Gürgün Tuğçe Vural Solak, Şenay Demir, Musa Topel, Dilek Çuhadar Erçelebi, İlkay Koca Kalkan, Hale Ateş, Gözde Köycü Buhari, Sakine Nazik Bahçecioğlu","doi":"10.1177/10781552231213318","DOIUrl":null,"url":null,"abstract":"Aim: To present the characteristics of drug hypersensitivity reactions (DHRs) among taxane recipients with non-small cell lung carcinoma (NSCLC), and to describe the results of rapid drug desensitization (RDD).Methods: A retrospective cross-sectional study included 45 patients who were treated with taxane for NSCLC and were found to be hypersensitive to taxane. All patients were administered the standard 3-bag, 12-step RDD protocol following the development of DHR. RDD success was evaluated separately for each cycle, and successful RDD was defined as the completion of the cycle with application of 12 steps of the desensitization protocol and the absence of early and/or late reactions afterwards.Results: Among 45 patients hypersensitive to taxane 43 (95.6%) successfully received taxane cycles with desensitization. Failed RDD occurred in only 2 (4.4%) patients. The total number of desensitization cycles was 183, of which 181 (98.9%) were successful. The mean age of patients with successful desensitization was 59.42 ± 10.48 years and 37 (86.0%) of them were male.Conclusion: RDD is a reliable procedure that enables effective administration and completion of first-line taxane treatments in taxane-sensitive patients.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1358-1363"},"PeriodicalIF":1.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552231213318","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To present the characteristics of drug hypersensitivity reactions (DHRs) among taxane recipients with non-small cell lung carcinoma (NSCLC), and to describe the results of rapid drug desensitization (RDD).

Methods: A retrospective cross-sectional study included 45 patients who were treated with taxane for NSCLC and were found to be hypersensitive to taxane. All patients were administered the standard 3-bag, 12-step RDD protocol following the development of DHR. RDD success was evaluated separately for each cycle, and successful RDD was defined as the completion of the cycle with application of 12 steps of the desensitization protocol and the absence of early and/or late reactions afterwards.

Results: Among 45 patients hypersensitive to taxane 43 (95.6%) successfully received taxane cycles with desensitization. Failed RDD occurred in only 2 (4.4%) patients. The total number of desensitization cycles was 183, of which 181 (98.9%) were successful. The mean age of patients with successful desensitization was 59.42 ± 10.48 years and 37 (86.0%) of them were male.

Conclusion: RDD is a reliable procedure that enables effective administration and completion of first-line taxane treatments in taxane-sensitive patients.

查看原文本刊更多论文

对紫杉烷的快速药物脱敏：一项来自土耳其的描述性研究。

目的：介绍紫杉烷受体非小细胞肺癌（NSCLC）药物超敏反应（DHRs）的特点，并描述快速药物脱敏（RDD）的结果。方法：一项回顾性横断面研究纳入了45名接受紫杉烷治疗的NSCLC患者，这些患者被发现对紫杉烷过敏。DHR发展后，所有患者均接受标准的3袋12步RDD方案。每个周期的RDD成功率分别进行评估，成功的RDD被定义为应用12个步骤的脱敏方案完成周期，并且之后没有早期和/或晚期反应。结果：45例紫杉烷过敏患者中，43例（95.6%）成功接受紫杉烷周期脱敏治疗。失败的RDD仅发生在2例（4.4%）患者中。脱敏周期总数为183个，其中181个（98.9%）成功。脱敏成功患者的平均年龄为59.42岁 ± 10.48岁，其中男性37例（86.0%）。结论：RDD是一种可靠的程序，能够有效地给药并完成紫杉烷敏感患者的一线紫杉烷治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oncology Pharmacy Practice Medicine-Oncology

CiteScore

2.70

自引率

7.70%

发文量

276

期刊介绍： Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...